Expansion of T memory stem cells with superior anti-tumor immunity by Urolithin A-induced mitophagy.
T(SCM)
anti-tumor immunity
mitophagy
Journal
Immunity
ISSN: 1097-4180
Titre abrégé: Immunity
Pays: United States
ID NLM: 9432918
Informations de publication
Date de publication:
08 11 2022
08 11 2022
Historique:
received:
01
03
2022
revised:
31
07
2022
accepted:
23
09
2022
entrez:
9
11
2022
pubmed:
10
11
2022
medline:
15
11
2022
Statut:
ppublish
Résumé
T memory stem cells (T
Identifiants
pubmed: 36351375
pii: S1074-7613(22)00508-8
doi: 10.1016/j.immuni.2022.09.014
pii:
doi:
Substances chimiques
3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one
1143-70-0
Coumarins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2059-2073.e8Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors have filed patents regarding the use of Urolithin in tumor therapy and CAR T cell generation. M.D. is an employee of AstraZeneca, UK. C.R. is CEO and a board member of Amazentis SA; P.A.A. is an employee of Vandria SA. F.R.G. has received consulting fees from Amazentis.